Inhibikase Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -36 | -23 | -24 | -12 |
EBITDA | -13,150 | -11,906 | -11,166 | -15,750 |
EBIT | -11,930 | -11,190 | -15,762 | |
Net Income | -12,734 | -11,930 | -9,915 | -13,678 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -7,967 | -10,592 | -5,574 | -4,103 |
Cash | 139,220 | 38,269 | 77,742 | 73,441 |
Basic Shares | 98,310 | 90,050 | 90,009 | 89,537 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $260 | $123 |
Gross Profit | -60 | -26 | -13,357 | 116 |
EBITDA | -45,887 | -27,493 | -19,912 | -18,047 |
EBIT | -45,948 | -27,519 | -20,089 | -18,054 |
Net Income | -48,259 | -27,519 | -19,028 | -18,054 |
Net Change In Cash | 0 | 0 | 260 | 123 |
Free Cash Flow | -27,786 | -19,148 | -18,099 | -17,594 |
Cash | 139,220 | 56,490 | 9,165 | 7,188 |
Basic Shares | 98,310 | 69,362 | 5,333 | 4,201 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | -$0.09 |
2025-09-30 | -$0.13 |
2025-06-30 | -$0.11 |
2025-03-31 | -$0.15 |
